Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0NLPAH
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Glypican 3 ADC
|
|||||
| Synonyms |
A2-tub; Glypican 3 ADC; Glypican 3 antibody drug conjugate; Glypican 3 antibody drug conjugate (Bristol-Myers Squibb); Glypican-3 ADC; Glypican3 ADC
Click to Show/Hide
|
|||||
| Organization |
Bristol Myers Squibb Co.
|
|||||
| Drug Status |
Phase 1 (Terminated)
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
1
|
|||||
| Antibody Name |
Adnectins scaffold protein
|
Antibody Info | ||||
| Antigen Name |
Glypican-3 (GPC3)
|
Antigen Info | ||||
| Payload Name |
Tubulysin analog Tub
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mal-EBE-Mal
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 100.00% | Positive GPC3 expression (GPC3+++/++) | ||
| Method Description |
Female NOD/SCID mice were inoculated subcutaneously in the right flank with 500,000 Hep3B cells. Three weekly administration of A2-tub at 0.12 mol/kg.
|
||||
| In Vivo Model | Hep3B CDX model | ||||
| In Vitro Model | Childhood hepatocellular carcinoma | Hep 3B2.1-7 cells | CVCL_0326 | ||
References